FTC Says Likely Pay-For-Delay Deals Remain Few
The number of potentially anti-competitive patent infringement litigation settlements between brand drugmakers and their would-be generic rivals continued to trend downward through the end of 2017, according to the Federal Trade...To view the full article, register now.
Already a subscriber? Click here to view full article